75.51
price up icon0.39%   0.29
after-market Dopo l'orario di chiusura: 75.51
loading
Precedente Chiudi:
$75.22
Aprire:
$75.73
Volume 24 ore:
594.12K
Relative Volume:
0.47
Capitalizzazione di mercato:
$3.70B
Reddito:
-
Utile/perdita netta:
$-38.99M
Rapporto P/E:
-25.20
EPS:
-2.9966
Flusso di cassa netto:
$-24.94M
1 W Prestazione:
+2.94%
1M Prestazione:
+2.44%
6M Prestazione:
+53.63%
1 anno Prestazione:
+69.15%
Intervallo 1D:
Value
$74.34
$76.25
Intervallo di 1 settimana:
Value
$72.96
$78.78
Portata 52W:
Value
$36.93
$80.99

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Name
Nome
Soleno Therapeutics Inc
Name
Telefono
650-213-8444
Name
Indirizzo
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Name
Dipendente
92
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
SLNO's Discussions on Twitter

Confronta SLNO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SLNO
Soleno Therapeutics Inc
75.51 3.70B 0 -38.99M -24.94M -2.9966
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-05 Ripresa Stifel Buy
2024-12-02 Reiterato Robert W. Baird Outperform
2024-12-02 Reiterato Stifel Buy
2024-09-03 Iniziato H.C. Wainwright Buy
2024-05-10 Iniziato Robert W. Baird Outperform
2024-02-05 Iniziato Piper Sandler Overweight
2024-01-23 Iniziato Stifel Buy
2023-11-21 Ripresa Guggenheim Buy
2020-09-29 Iniziato Guggenheim Buy
2020-01-10 Iniziato Craig Hallum Buy
2019-12-23 Iniziato Oppenheimer Outperform
2018-02-13 Reiterato Maxim Group Buy
Mostra tutto

Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie

pulisher
Jun 06, 2025

Soleno Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 06, 2025
pulisher
Jun 05, 2025

Transcript : Soleno Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com

Jun 05, 2025
pulisher
Jun 04, 2025

Trading (SLNO) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 04, 2025
pulisher
May 27, 2025

Soleno Therapeutics’ SWOT analysis: vykat xr launch propels stock amid rare disease market potential - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Soleno Therapeutics stock Buy rating, $108 target - Investing.com

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Soleno Therapeutics stock Buy rating, $108 target By Investing.com - Investing.com India

May 27, 2025
pulisher
May 26, 2025

EMA validates Soleno’s application for Prader-Willi syndrome treatment - Yahoo Finance

May 26, 2025
pulisher
May 25, 2025

(SLNO) Trading Report - news.stocktradersdaily.com

May 25, 2025
pulisher
May 23, 2025

Soleno Therapeutics seeking regulatory approval in treatment of PWS - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Friday - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Soleno Application for Hyperphagia Treatment in Patients with Prader-Willi Syndrome Gets European Validation - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR - Insider Monkey

May 23, 2025
pulisher
May 23, 2025

Soleno seeks EU approval for Prader-Willi syndrome treatment - Investing.com Australia

May 23, 2025
pulisher
May 22, 2025

Soleno seeks EU approval for Prader-Willi syndrome treatment By Investing.com - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Soleno Therapeutics' (SLNO) MAA for PWS Treatment Validated by EMA | SLNO Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Soleno Therapeutics Announces Submission and EMA Validation - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

Soleno's PWS Drug VYKAT Advances in Europe After Recent FDA ApprovalKey Details for Investors - Stock Titan

May 22, 2025
pulisher
May 22, 2025

BCE Inc: Stock Forecast & Analysis - The Globe and Mail

May 22, 2025
pulisher
May 22, 2025

Buy AT&T or Verizon Stock if Market Volatility Resurges? - The Globe and Mail

May 22, 2025
pulisher
May 22, 2025

Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock - Investing.com Australia

May 22, 2025
pulisher
May 21, 2025

Soleno Therapeutics to Participate in Upcoming June Conferences - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Lowe’s Stock Uptrend Can Continue for These 2 Reasons - The Globe and Mail

May 21, 2025
pulisher
May 21, 2025

Rare Disease Leader Soleno Therapeutics Secures Speaking Slots at Major Healthcare Conferences - Stock Titan

May 21, 2025
pulisher
May 21, 2025

Piper Sandler maintains $145 target on Soleno Therapeutics stock - Investing.com Australia

May 21, 2025
pulisher
May 20, 2025

Soleno reports positive VYKAT XR results for Prader-Willi syndrome By Investing.com - Investing.com South Africa

May 20, 2025
pulisher
May 20, 2025

Piper Sandler maintains $145 target on Soleno Therapeutics stock By Investing.com - Investing.com Canada

May 20, 2025
pulisher
May 20, 2025

Soleno reports positive VYKAT XR results for Prader-Willi syndrome - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Resu - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Results | SLNO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Soleno Therapeutics Presents Positive Clinical Data for VYKAT™ XR at the 2025 Pediatric Endocrine Society Annual Meeting - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants wi - The Manila Times

May 20, 2025
pulisher
May 20, 2025

VYKAT XR Clinical Data Shows Major Improvements in Prader-Willi Syndrome Symptoms | SLNO Stock News - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 20, 2025
pulisher
May 19, 2025

Company News for May 19, 2025 - The Globe and Mail

May 19, 2025
pulisher
May 18, 2025

Northern Trust Corp Buys 34,309 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World

May 18, 2025
pulisher
May 15, 2025

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

New Clinical Data Shows VYKAT XR Improves Body Mass and Behavior in Prader-Willi Syndrome Patients - Stock Titan

May 15, 2025
pulisher
May 13, 2025

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - GlobeNewswire

May 13, 2025
pulisher
May 12, 2025

SLNO FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World

May 12, 2025
pulisher
May 11, 2025

Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now? - Insider Monkey

May 11, 2025
pulisher
May 11, 2025

11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey

May 11, 2025
pulisher
May 10, 2025

Got $3,000? 2 Artificial Intelligence (AI) Stocks to Buy and Hold for the Long Term - The Globe and Mail

May 10, 2025

Soleno Therapeutics Inc Azioni (SLNO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Capitalizzazione:     |  Volume (24 ore):